Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PQS (software)

Biological Assembly 2  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors and generated by PQS (software)

Macromolecule Content

• Total Structure Weight: 134.00 kDa 
• Atom Count: 8624 
• Residue Count: 1114 
• Unique protein chains: 1

2BXH

Human serum albumin complexed with indoxyl sulfate

• DOI: 10.2210/pdb2BXH/pdb

• Classification: TRANSPORT PROTEIN
• Organism(s): Homo sapiens
• Expression System: Komagataella pastoris
• Mutation(s): No 


• Deposited: 2005-07-26 Released: 2005-09-22 
• Deposition Author(s): Ghuman, J., Zunszain, P.A., Petitpas, I., Bhattacharya, A.A., Curry, S.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.25 Å
• R-Value Free: 0.266 
• R-Value Work: 0.227 
• R-Value Observed: 0.227 

Literature

Structural Basis of the Drug-Binding Specificity of Human Serum Albumin.

Ghuman, J., Zunszain, P.A., Petitpas, I., Bhattacharya, A.A., Otagiri, M., Curry, S.

(2005) J Mol Biol 353: 38

• PubMed: 16169013 
• DOI: 10.1016/j.jmb.2005.07.075
• Structures With Same Primary Citation


• PubMed Abstract: 
  

Human serum albumin (HSA) is an abundant plasma protein that binds a remarkably wide range of drugs, thereby restricting their free, active concentrations. The problem of overcoming the binding affinity of lead compounds for HSA represents a major challenge in drug development. Crystallographic analysis of 17 different complexes of HSA with a wide variety of drugs and small-molecule toxins reveals the precise architecture of the two primary drug-binding sites on the protein, identifying residues that are key determinants of binding specificity and illuminating the capacity of both pockets for flexible accommodation. Numerous secondary binding sites for drugs distributed across the protein have also been identified. The binding of fatty acids, the primary physiological ligand for the protein, is shown to alter the polarity and increase the volume of drug site 1. These results clarify the interpretation of accumulated drug binding data and provide a valuable template for design efforts to modulate the interaction with HSA.

---

Organizational Affiliation: 

Biophysics Section, Division of Cell and Molecular Biology, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
SERUM ALBUMIN	A, B	585	Homo sapiens	Mutation(s): 0  Gene Names: ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341
Find proteins for P02768 (Homo sapiens) Go to UniProtKB:  P02768
NIH Common Fund Data Resources
PHAROS  P02768 GTEx  ENSG00000163631

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
IOS	A, B	3-SULFOOXY-1H-INDOLE C8 H7 N O4 S BXFFHSIDQOFMLE-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.25 Å
• R-Value Free: 0.266 
• R-Value Work: 0.227 
• R-Value Observed: 0.227 
• Space Group: P 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 54.71	α = 81.27
b = 55.2	β = 91.09
c = 119.88	γ = 65.29

Software Package:

Software Name	Purpose
CNS	refinement
MOSFLM	data reduction
SCALA	data scaling
CNS	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2005-07-26 
• Released Date: 2005-09-22 
Deposition Author(s): Ghuman, J., Zunszain, P.A., Petitpas, I., Bhattacharya, A.A., Curry, S.

Revision History 

• Version 1.0: 2005-09-22
  Type: Initial release
  
• Version 1.1: 2011-05-08
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance
• Version 1.3: 2019-07-24
  Changes: Data collection